Bicara Therapeutics (BCAX) Profit After Tax (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Profit After Tax of -$56.2 million for Q1 2026, down 52.56% year-over-year from -$118.5 million in Q1 2025, and down 14931.4% quarter-over-quarter from $379000.0 in Q4 2025.
Bicara Therapeutics (BCAX) Profit After Tax (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Profit After Tax history runs 4 years deep, the most recent figure standing at -$56.2 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 52.56% year-over-year to -$56.2 million; the TTM figure through Mar 2026 stood at -$119.7 million (down 59.9% YoY), while the FY2025 annual figure was $243000.0, up 100.36% from the prior year.
- Profit After Tax for Q1 2026 stood at -$56.2 million, down from $379000.0 in the prior quarter.
- The five-year high for Profit After Tax was $379000.0 in Q4 2025, with the low at -$56.2 million in Q1 2026.
- The 4-year median for Profit After Tax is -$21.9 million (2023), against an average of -$24.2 million.
- Peak annual rise in Profit After Tax reached 101.81% in 2025, while the deepest fall reached 194.58% in 2025.
- Bicara Therapeutics' Profit After Tax stood at -$12.4 million in 2023, then sank by 68.46% to -$21.0 million in 2024, then surged by 101.81% to $379000.0 in 2025, then slumped by 14931.4% to -$56.2 million in 2026.
- Business Quant data shows BCAX's Profit After Tax at -$56.2 million in Q1 2026, $379000.0 in Q4 2025, and -$36.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | -55.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.76 Mn |
| Mar 31, 2026 | -56.21 Mn |
| Dec 31, 2025 | 379,000.00 |
| Sep 30, 2025 | -36.47 Mn |
| Jun 30, 2025 | -27.39 Mn |
| Mar 31, 2025 | -36.85 Mn |
| Dec 31, 2024 | -20.96 Mn |
| Jun 30, 2024 | -17.05 Mn |
| Mar 31, 2024 | -12.51 Mn |
| Dec 31, 2023 | -12.44 Mn |
| Sep 30, 2023 | -22.85 Mn |